Biostable nucleic acid aptamers for long-duration, in vivo molecular monitoring
用于长时间体内分子监测的生物稳定核酸适体
基本信息
- 批准号:10430240
- 负责人:
- 金额:$ 23.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-15 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Respiratory Distress SyndromeAminoglycosidesAnimal ModelAntibioticsBindingBiological MarkersBiotechnologyBloodBrainCOVID-19ChemicalsClinicalCommunicable DiseasesContinuous Glucose MonitorCreatinineDevelopmentDiabetes MellitusDiagnosisDiagnosticDiameterDiseaseDoseDose LimitingDrug KineticsElectrodesElectron TransportElementsEngineeringExhibitsFeedbackGlucoseGoalsHealthHealth StatusHormonesHourIn SituIn VitroInfectionMeasurableMeasurementMeasuresMedical ResearchMolecularMonitorMuscleNucleic AcidsOligonucleotidesOutcomeOutputOxidation-ReductionPatientsPerformancePharmaceutical PreparationsPreclinical TestingProcessRattusRenal functionReporterReportingResearchResistanceSafetySepsisSignal TransductionSiteSolidSpecificitySurfaceTechnologyTherapeuticTherapeutic IndexTimeTissuesTobramycinToxic effectVancomycinVertebral columnWhole BloodWidowWidowhoodWorkaptamerawakeclinical practiceclinically actionableclinically relevantcytokinediagnostic biomarkerdrug efficacyfabricationfallsimprovedin vitro testingin vivoin vivo evaluationin vivo monitoringinnovationmeterminimally invasivemonolayeroxidationprecision drugsprotein biomarkersreal time monitoringresearch clinical testingself assemblysensortemporal measurementtreatment duration
项目摘要
Summary. Electrochemical, aptamer-based (EAB) sensors are a minimally invasive technology already shown
to support seconds-resolved, real-time, in vivo molecular measurements irrespective of the chemical reactivity
of its targets. That is, EAB sensors are the only real-time molecular measurement technology that is
simultaneously (1) generalizable to drugs and biomarkers and (2) demonstrated to work in situ in the body. In
support of these claims, as preliminary results we have reported the first ever seconds- (and even sub-second)
resolved, in-vivo measurements of multiple drugs and protein biomarkers. These measurements, which employ
75-µm-diameter sensors placed in situ in the blood (jugular) and tissues (brain, muscle) of awake, freely moving
rats, achieve clinically relevant accuracy, precision and specificity over the course of hours. A remaining
technological limitation, however, still precludes the further clinical testing of EAB sensors: after more than after
~5 h in vivo, aptamer degradation begins to reduce EAB precision significantly. The R21 project described here
is focused on solving this problem. Specifically, here we propose the introduction of degradation-resistant,
non-natural XNA aptamers into the EAB platform as a means achieving multi-day in vivo molecular
measurements. Successful conclusion of this work would set the stage for R01-scale projects aimed at
ascertaining the clinical value of long-duration EAB measurements in, for example, the feedback-controlled
delivery of narrow-therapeutic-index antibiotics over multi-day treatment courses and the real-time monitoring of
diagnostic cytokines in the ICU over the multi-day clinical course of infections, such as in sepsis and COVID-19.
摘要电化学,适体为基础的(EAB)传感器是一种微创技术已经显示
以支持秒级分辨的实时体内分子测量,而不管化学反应性如何
它的目标。也就是说,EAB传感器是唯一的实时分子测量技术,
同时(1)可推广到药物和生物标志物和(2)证明在体内原位起作用。在
支持这些说法,作为初步结果,我们已经报告了有史以来第一次秒-(甚至亚秒)
多种药物和蛋白质生物标志物的解析的体内测量。这些测量方法,
75微米直径的传感器原位放置在清醒、自由运动的人的血液(颈静脉)和组织(大脑、肌肉)中
大鼠,达到临床相关的准确性,精密度和特异性在数小时的过程。剩余
然而,技术上的限制仍然阻碍了EAB传感器的进一步临床测试:
在体内约5 h,适体降解开始显著降低EAB精度。这里描述的R21项目
是专注于解决这个问题。具体来说,在这里,我们建议引入抗降解,
将非天然XNA适体引入EAB平台作为实现多日体内分子生物学特性的手段。
测量.这项工作的成功完成将为R 01规模的项目奠定基础,
确定长期EAB测量的临床价值,例如,反馈控制
在多天疗程内提供窄治疗指数抗生素,并实时监测
在ICU中的诊断性细胞因子在感染的多日临床过程中,例如在败血症和COVID-19中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin W Plaxco其他文献
Kevin W Plaxco的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin W Plaxco', 18)}}的其他基金
Biostable nucleic acid aptamers for long-duration, in vivo molecular monitoring
用于长时间体内分子监测的生物稳定核酸适体
- 批准号:
10304801 - 财政年份:2021
- 资助金额:
$ 23.4万 - 项目类别:
Feedback controlled, ultra-high-precision drug delivery
反馈控制的超高精度药物输送
- 批准号:
10084266 - 财政年份:2019
- 资助金额:
$ 23.4万 - 项目类别:
Feedback controlled, ultra-high-precision drug delivery
反馈控制的超高精度药物输送
- 批准号:
10321612 - 财政年份:2019
- 资助金额:
$ 23.4万 - 项目类别:
Feedback controlled, ultra-high-precision drug delivery
反馈控制的超高精度药物输送
- 批准号:
9761770 - 财政年份:2019
- 资助金额:
$ 23.4万 - 项目类别:
Bio-electrochemical detectors for in vivo continuous monitoring
用于体内连续监测的生物电化学检测器
- 批准号:
9238429 - 财政年份:2017
- 资助金额:
$ 23.4万 - 项目类别:
Bio-electrochemical detectors for in vivo continuous monitoring
用于体内连续监测的生物电化学检测器
- 批准号:
9551624 - 财政年份:2017
- 资助金额:
$ 23.4万 - 项目类别:
A new approach to quantitative, point-of-care serology
定量、护理点血清学的新方法
- 批准号:
9306748 - 财政年份:2014
- 资助金额:
$ 23.4万 - 项目类别:
A new tool for measuring surface-biomolecule interactions
测量表面生物分子相互作用的新工具
- 批准号:
8662567 - 财政年份:2014
- 资助金额:
$ 23.4万 - 项目类别:
相似海外基金
Aminoglycosides with reduced ototoxicity via miRNA targeting
通过 miRNA 靶向降低耳毒性的氨基糖苷类药物
- 批准号:
9891947 - 财政年份:2019
- 资助金额:
$ 23.4万 - 项目类别:
Aminoglycosides with reduced ototoxicity via miRNA targeting
通过 miRNA 靶向降低耳毒性的氨基糖苷类药物
- 批准号:
9982540 - 财政年份:2019
- 资助金额:
$ 23.4万 - 项目类别:
Antibacterial properties of amphiphilic aminoglycosides
两亲性氨基糖苷类药物的抗菌特性
- 批准号:
524825-2018 - 财政年份:2018
- 资助金额:
$ 23.4万 - 项目类别:
University Undergraduate Student Research Awards
Nanobiocapteurs de résonance des plasmons de surface pour les aminoglycosides
氨基糖苷类表面等离激元共振的纳米生物捕获剂
- 批准号:
495915-2016 - 财政年份:2016
- 资助金额:
$ 23.4万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Designing new aminoglycosides to alleviate inner ear toxicity
设计新的氨基糖苷类药物以减轻内耳毒性
- 批准号:
8943277 - 财政年份:2015
- 资助金额:
$ 23.4万 - 项目类别: